Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea
NCT ID: NCT02810509
Last Updated: 2019-09-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1814 participants
OBSERVATIONAL
2015-06-30
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
NCT00448214
The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients
NCT02646267
Clinical and Laboratory Predictors Associated With Stroke or Systemic Embolism in Low Risk Atrial Fibrillation Patients
NCT03147911
Gene-guided Warfarin for Anticoagulation Therapy
NCT04482842
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
NCT03572972
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To explore predictors for poor INR control.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Short-term Warfarin-treated cohort
1. admission due to AF-related ischemic stroke (known AF or newly detected AF)
2. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
3. TTR evaluable days \< 90 days
No interventions assigned to this group
Long-term Warfarin-treated cohort
1. admission due to AF-related ischemic stroke (known AF or newly detected AF)
2. long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
3. for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
4. TTR evaluable days ≥ 90 days
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period
3. For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment
1. Admission due to AF-related ischemic stroke
2. Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
3. For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment
4. TTR evaluable days ≥ 90 days
Exclusion Criteria
2. Enrollment in anticoagulation randomized clinical trial
3. Enrollment in studies affecting the target INR range.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inje University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Keun-Sik Hong
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Keun-Sik Hong, MD, Phd
Role: PRINCIPAL_INVESTIGATOR
Department of Neurology, Ilsan Paik Hospital Inje University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hallym University College of Medicine
Anyang, , South Korea
Dong-A University College of Medicine
Busan, , South Korea
Yeungnam University School of Medicine
Daegu, , South Korea
Dongguk University Ilsan Hospital
Goyang, , South Korea
Chonnam National University Medical School
Gwangju, , South Korea
Ilsan Paik Hospital Inje University
Ilsan, , South Korea
Inha University Hospital
Incheon, , South Korea
Jeju National University Hospital, Jeju National University College of Medicine
Jeju City, , South Korea
Seoul National University Bundang Hospital
Seongnam, , South Korea
Eulji General Hospital, Eulji University School of Medicine
Seoul, , South Korea
Korea University College of Medicine
Seoul, , South Korea
Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, , South Korea
Seoul Medical Center
Seoul, , South Korea
Seoul National University College of Medicine
Seoul, , South Korea
Soonchunhyang University College of Medicine
Seoul, , South Korea
Soonchunhyang University
Seoul, , South Korea
University of Ulsan College of Medicine
Seoul, , South Korea
Yonsei University College of Medicine
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Warfarin TTR-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.